2022 American Transplant Congress
The Successful Use of De Novo Belatacept with Reduced Dose Tacrolimus to Mitigate the Risks of Delayed Graft Function in Kidney Transplantation
*Purpose: The new kidney allocation system has caused increased organ travel times and therefore increased cold ischemia time. Furthermore, the change in the priority to…2022 American Transplant Congress
Meta-Analysis of the Chronic Exposure to Calcineurin Inhibitors and the Risk for Chronic and End-Stage Kidney Disease in Non-Renal Solid Organ Transplant Recipients
*Purpose: Calcineurin inhibitors (CNI) are standard of care immunosuppressants among all solid organ transplant (SOT) recipients, and the most common side effect is nephrotoxicity. There…2022 American Transplant Congress
Direct Comparison of Clinical Outcomes with Belatacept-Based Regimens to Calcineurin Inhibitors Among DCD and/or High KDPI Kidney Transplant Recipients
*Purpose: Belatacept, an inhibitor of the T-cell costimulatory pathway, can be used in recipients of Donation after Cardiac Death (DCD) and high Kidney Donor Profile…2022 American Transplant Congress
Impact of Belatacept Conversion on Renal Function and Donor Specific Antibodies in Renal Transplant Recipients
Northwestern Memorial Hospital, Chicago, IL
*Purpose: Although associated with nephrotoxicity, calcineurin inhibitors (CNI) have historically been the cornerstone of immunosuppression. Belatacept, a co-stimulation blocker, is FDA-approved for de novo use…2022 American Transplant Congress
Tacrolimus Induces Dedifferentiation of Pancreatic Beta Cells by Inhibition of Calcineurin/NFATc2 and Islet Cell Differentiation Genes
*Purpose: Tacrolimus (FK506) is a potent immunosuppressant widely used for solid organ transplantation to prevent lymphokine gene expression by inhibiting calcineurin (CN) and its downstream…2022 American Transplant Congress
Long-Term Low-Dose Corticosteroid Therapy Can Suppress Calcineurin Inhibitor Induced Nephrotoxicity without Steroid-Related Complication in Living Kidney Transplant Recipient
Sapporo City General Hospital, Sapporo, Japan
*Purpose: The induction of calcineurin inhibitors (CNI) greatly reduced the rate of allograft rejection, although their chronic use resulted in vascular inflammation in kidney transplant…2022 American Transplant Congress
Post Transplant Virologic Outcomes in DCD Kidney Transplant Recipients Treated with Thymoglobulin Induction Immunosuppression and Maintenance Belatacept vs Calcineurin Inhibitor Therapy
*Purpose: Belatacept is an inhibitor of the T-Cell costimulatory pathway that can be used in recipients of Donation after Circulatory Death (DCD) where the intended…2022 American Transplant Congress
Pediatric Liver Transplant Factors That Influence Tacrolimus Absorption
1Children's Hospital Colorado, Aurora, CO, 2University of Colorado, Aurora, CO
*Purpose: The aim of this study was to investigate the association between various pediatric recipient characteristics at time of liver transplant and FK506 absorption 6…2022 American Transplant Congress
Impact of Biliary Reconstruction on Tacrolimus Absorption in Pediatric Liver Transplant
1Children's Hospital Colorado, Aurora, CO, 2University of Colorado, Aurora, CO
*Purpose: Tacrolimus (FK506) oral bioavailability in pediatric liver transplant recipients (LTR) is poor. Enteral FK506 is primarily absorbed in the small intestine and subject to…2022 American Transplant Congress
Post-Kidney Transplant Dementia Risk by Modifiable Risk Factors and CNIs Among Older Recipients
*Purpose: Up to 17% of older recipients develop dementia after kidney transplant (KT). While there are known modifiable risk factors for dementia among community-dwelling older…
- 1
- 2
- 3
- …
- 16
- Next Page »